Takeda Advances Orexin-Mimicking Narcolepsy Drug TAK-360 Into Active Mid-Stage Testing

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.

Study Overview

Takeda’s new trial, officially titled “A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants With Narcolepsy Without Cataplexy (NT2),” is testing a novel wake-promoting pill in adults with narcolepsy type 2. The study aims to see how safe the drug is, how well patients tolerate it, and whether it helps them stay awake during the day, a key unmet need in this chronic sleep disorder.

Intervention/Treatment

The main treatment is TAK-360, an oral drug designed to act like orexin, a natural brain chemical that supports wakefulness and alertness. Participants will receive either TAK-360 tablets or matching placebo tablets. The goal is to find a dose that improves daytime alertness while keeping side effects manageable.

Study Design

This is an interventional Phase 2 study with patients randomly assigned to either TAK-360 or placebo, in parallel groups. It is double-blind for participants, doctors, trial staff, and outcome assessors, which means no one knows who gets the active drug or placebo during the trial. The main purpose is treatment, with a focus on measuring safety, tolerability, and signs of benefit on daytime sleepiness.

Study Timeline

The study was first submitted on April 23, 2025, marking the formal start of regulatory tracking and signaling that recruitment planning was underway. The trial is currently listed as “recruiting,” indicating active enrollment and ongoing dosing of participants. The most recent update to the record was submitted on February 4, 2026, which suggests the protocol, timelines, or site information were refreshed and that the program remains active. Primary completion and final completion dates have not yet been reported, so top-line results are still a future catalyst.

Market Implications

For investors, this update reinforces Takeda’s push into central nervous system disorders and its interest in orexin-based therapies, an emerging class that has attracted attention from both large pharma and smaller biotechs. A positive readout could open a meaningful new market in narcolepsy type 2, support premium pricing for a differentiated drug, and strengthen Takeda’s neurology franchise, which can be a key offset to patent expiries elsewhere in its portfolio. In the near term, the recruiting status and recent update mainly signal execution progress rather than de-risking; however, they help maintain confidence that the company is moving on schedule toward value-inflecting data. Competitors working on sleep-wake and orexin pathways may see increased investor focus as the space matures, but until efficacy data arrives, market impact will stay sentiment-driven rather than fundamental. The study remains ongoing and updated, with further details available on the ClinicalTrials portal.

To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.